{"success":true,"data":{"pressRelease":{"id":"125654","rtpr_id":"nBw7zbjrja","ticker":"DTIL","exchange":"NASDAQ","all_tickers":["DTIL"],"title":"Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study","author":"Business Wire","published_at":"2026-08-24T10:01:00.078Z","article_body":"Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study\n\n-First patient dosed with PBGENE-DMD, the first clinical gene-editing program\nfor DMD –\n\n-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified\nDuchenne Care Center and designated MDA Care Center–\n\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing\ncompany utilizing its novel proprietary ARCUS(®) platform to develop in vivo\ngene editing therapies for high unmet need diseases, today announced the\ndosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical\ntrial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy\n(DMD).\n\nPBGENE-DMD is Precision's wholly owned in vivo gene editing program designed\nto durably improve function. This novel approach, aiming to restore near\nfull-length dystrophin, is applicable for up to 60% of DMD patients with\nmutations in a key hot spot region. By employing two complementary ARCUS\nnucleases in a single AAV, PBGENE-DMD excises exons 45-55 of the dystrophin\ngene with the aim of restoring a near full-length functional dystrophin\nprotein that more closely resembles normal dystrophin than synthetic,\ntruncated microdystrophin approaches.\n\n“Dosing the first patient in the FUNCTION-DMD study earlier this month was a\nsignificant milestone for Precision BioSciences and for the Duchenne\ncommunity,” said Sam Collins, M.D., Senior Vice President, DMD Clinical\nDevelopment of Precision BioSciences. “PBGENE-DMD represents a paradigm\nshift from currently available approaches. Rather than delivering a highly\ntruncated form of synthetic dystrophin as many therapies in development do\ntoday, PBGENE-DMD is designed to permanently edit the patient’s own\ndystrophin gene to endogenously produce a near full-length, functional\ndystrophin protein. We are grateful to the patient, their family, and the\nclinical team for their commitment to advancing this important work, and we\nlook forward to reporting initial safety data by year-end 2026.”\n\n“A therapy designed to address the underlying genetic cause of Duchenne\nmuscular dystrophy represents a meaningful step forward for individuals and\nfamilies living with this condition,” said Aravindhan Veerapandiyan, M.D.,\nDirector of the Comprehensive Neuromuscular Program at Arkansas Children’s\nHospital. “We’re proud that our center was the first to dose a patient in\nthe FUNCTION-DMD study. PBGENE-DMD is designed to restore near full-length,\nfunctional dystrophin, and we look forward to evaluating its safety and\npotential to provide durable functional benefits. This innovation could open\nthe door to an entirely new approach for treating Duchenne.”\n\n“Seeing PBGENE-DMD move from research into the clinic turns the possibility\nof gene editing for Duchenne into reality — a novel approach that could\naddress some of the limitations of currently available therapies,” said Pat\nFurlong, President, Parent Project Muscular Dystrophy. “Families have been\nwaiting for options like this, and PPMD is encouraged to see this program\nadvance. We look forward to learning more as the study progresses and\ncontinuing collaboration on behalf of all our Duchenne families.”\n\nThe study is currently enrolling ambulatory DMD patients between the ages of 2\nand 7 with mutations between exons 45 and 55, representing up to 60% of boys\nliving with DMD, across multiple U.S. clinical trial sites. The study is\nactively recruiting patients at specialized Duchenne care centers with initial\nsafety data expected by year-end 2026.\n\nAbout the FUNCTION-DMD Trial\n\nThe Phase 1/2 FUNCTION-DMD study is enrolling ambulatory DMD patients between\nthe ages of 2 and 7 with mutations between exons 45 and 55 representing up to\n60% of boys with DMD. The objective of the FUNCTION-DMD study is to evaluate\nsafety, tolerability, and efficacy, including dystrophin protein expression\nand functional outcomes in patients living with DMD. For more information\nabout this clinical trial and contact information, please visit\nwww.clinicaltrials.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.clinicaltrials.gov&esheet=54593368&newsitemid=20260824221319&lan=en-US&anchor=www.clinicaltrials.gov&index=1&md5=746a66ffd606885e24566b2fb909b310)\nand search for NCT07429240.\n\nAbout PBGENE-DMD, A Muscle-Targeted Excision Program\n\nPBGENE-DMD is Precision’s development program for the treatment of DMD. DMD\nis a genetic disease caused by mutations in the dystrophin gene that prevent\nproduction of the dystrophin protein and affects approximately 15,000 patients\nin the U.S. alone. There are currently no approved therapies that can drive\ndurable and significant functional improvements over time. PBGENE-DMD is\ndesigned to improve function by employing two complementary ARCUS nucleases\ndelivered in a single AAV to excise exons 45-55 of the dystrophin gene. The\naim of this approach is to restore a near full-length functional dystrophin\nprotein within the body that more closely resembles normal dystrophin as\nopposed to synthetic, truncated microdystrophin approaches with potentially\nminimal functional benefit. The Phase 1/2 FUNCTION-DMD study is enrolling\nambulatory DMD patients with mutations between exons 45 and 55 impacting up to\n60% of boys with DMD. The clinical trial employs an appropriate immune\nmodulation regimen and safety monitoring program to treat ambulatory patients\nat world-class specialized DMD clinical sites.\n\nPBGENE-DMD was granted Orphan Drug Designation by the FDA in July 2025. The\nPBGENE-DMD program is eligible for a Priority Review Voucher (PRV) via the\nRare Pediatric Disease program, which was signed into law on February 3, 2026,\nas part of the Consolidated Appropriations Act of 2026. PBGENE-DMD received\nFast Track designation from the FDA in February 2026.\n\nAbout Precision BioSciences, Inc.\n\nPrecision BioSciences, Inc. is a clinical stage gene editing company dedicated\nto improving life (DTIL) with its novel and proprietary ARCUS(®) genome\nediting platform that differs from other technologies in the way it cuts, its\nsmaller size, and its simpler structure. These features are intended for ARCUS\nnucleases to drive more defined therapeutic outcomes. Using ARCUS, the\nCompany’s pipeline is comprised of clinical stage in vivo gene editing\ncandidates designed to deliver lasting cures for the broadest range of genetic\nand infectious diseases where no adequate treatments exist. For more\ninformation about Precision BioSciences, please visit\nwww.precisionbiosciences.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.precisionbiosciences.com&esheet=54593368&newsitemid=20260824221319&lan=en-US&anchor=www.precisionbiosciences.com&index=2&md5=1d97c988828ba62536563caed30f9532)\n.\n\nThe ARCUS(®) platform is being used to develop in vivo gene editing therapies\nfor sophisticated gene edits, including gene elimination (removing a genome\ne.g. viral DNA such as in the Company’s PBGENE-HBV program), excision\n(removing a large portion of a defective gene by delivering two ARCUS\nnucleases in a single AAV such as in the Company’s PBGENE-DMD program), and\ngene insertion (inserting DNA into gene to cause expression/add function).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements contained\nin this press release that do not relate to matters of historical fact should\nbe considered forward-looking statements, including, without limitation,\nexpectations around patient enrollment and data releases of PBGENE-DMD and the\nFUNCTION-DMD trial, including initial safety data expected by year-end 2026;\ntranslation of results in preclinical studies of PBGENE-DMD to clinical\nstudies in humans; expectations around PBGENE-DMD as a novel approach that\ncould address some of the limitations of currently available therapies; and\nthe expected use of an appropriate immune modulation regimen and safety\nmonitoring program to treat ambulatory patients at world-class specialized DMD\nclinical sites . In some cases, you can identify forward-looking statements by\nterms such as “aim,” “anticipate,” “approach,” “belief,”\n“believe,” “contemplate,” “could,” “design,” “designed,”\n“estimate,” “expect,” “goal,” “intend,” “look,” “may,”\n“mission,” “plan,” “possible,” “potential,” “predict,”\n“project,” “pursue,” “should,” “strive,” “suggest,”\n“target,” “will,” “would,” or the negative thereof and similar\nwords and expressions.\n\nForward-looking statements are based on management’s current expectations,\nbeliefs, and assumptions and on information currently available to us. These\nstatements are neither promises nor guarantees, and involve a number of known\nand unknown risks, uncertainties and assumptions, and actual results may\ndiffer materially from those expressed or implied in the forward-looking\nstatements due to various important factors, including, but not limited to,\nour ability to become profitable; our ability to procure sufficient funding to\nadvance our programs; risks associated with our capital requirements,\nanticipated cash runway, requirements under our current debt instruments and\neffects of restrictions thereunder, including our ability to raise additional\ncapital due to market conditions and/or our market capitalization; our\noperating expenses and our ability to predict what those expenses will be; our\nlimited operating history; the progression and success of our programs and\nproduct candidates in which we expend our resources; our limited ability or\ninability to assess the safety and efficacy of our product candidates; the\nrisk that other genome-editing technologies may provide significant advantages\nover our ARCUS technology; our dependence on our ARCUS technology; the\ninitiation, cost, timing, progress, achievement of milestones and results of\nresearch and development activities and preclinical and clinical studies,\nincluding clinical trial and investigational new drug applications; public\nperception about genome editing technology and its applications; competition\nin the genome editing, biopharmaceutical, and biotechnology fields; our or our\ncollaborators’ or other licensees’ ability to identify, develop and\ncommercialize product candidates; pending and potential product liability\nlawsuits and penalties against us or our collaborators or other licensees\nrelated to our technology and our product candidates; the U.S. and foreign\nregulatory landscape applicable to our and our collaborators’ or other\nlicensees’ development of product candidates; our or our collaborators’ or\nother licensees’ ability to advance product candidates into, and\nsuccessfully design, implement and complete, clinical trials; potential\nmanufacturing problems associated with the development or commercialization of\nany of our product candidates; delays or difficulties in our and our\ncollaborators’ and other licensees’ ability to enroll patients; changes in\ninterim “top-line” and initial data that we announce or publish; if our\nproduct candidates do not work as intended or cause undesirable side effects;\nrisks associated with applicable healthcare, data protection, privacy and\nsecurity regulations and our compliance therewith; our or our licensees’\nability to obtain orphan drug designation or fast track designation for our\nproduct candidates or to realize the expected benefits of these designations;\nour or our collaborators’ or other licensees’ ability to obtain and\nmaintain regulatory approval of our product candidates, and any related\nrestrictions, limitations and/or warnings in the label of an approved product\ncandidate; the rate and degree of market acceptance of any of our product\ncandidates; our ability to effectively manage the growth of our operations;\nour ability to attract, retain, and motivate executives and personnel; effects\nof system failures and security breaches; insurance expenses and exposure to\nuninsured liabilities; effects of tax rules; effects of any pandemic,\nepidemic, or outbreak of an infectious disease; the success of our existing\ncollaboration and other license agreements, and our ability to enter into new\ncollaboration arrangements; our current and future relationships with and\nreliance on third parties including suppliers and manufacturers; our ability\nto obtain and maintain intellectual property protection for our technology and\nany of our product candidates; potential litigation relating to infringement\nor misappropriation of intellectual property rights; effects of natural and\nmanmade disasters, public health emergencies and other natural catastrophic\nevents; effects of sustained inflation, supply chain disruptions and major\ncentral bank policy actions; market and economic conditions; risks related to\nownership of our common stock, including fluctuations in our stock price; our\nability to meet the requirements of and maintain listing of our common stock\non Nasdaq or other public stock exchanges; and other important factors\ndiscussed under the caption “Risk Factors” in our Annual Report on Form\n10-K for the annual period ended December 31, 2025 and Quarterly Report on\nForm 10-Q for the quarterly period ended June 30, 2026, as any such factors\nmay be updated from time to time in our other filings with the SEC, which are\naccessible on the SEC’s website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54593368&newsitemid=20260824221319&lan=en-US&anchor=www.sec.gov&index=3&md5=cb1f6bce7f2f2c46d90498a92f68128b)\nand the Investors page of our website under SEC Filings at\ninvestor.precisionbiosciences.com.\n\nAll forward-looking statements speak only as of the date of this press release\nand, except as required by applicable law, we have no obligation to update or\nrevise any forward-looking statements contained herein, whether as a result of\nany new information, future events, changed circumstances or otherwise.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260824221319/en/\n(https://www.businesswire.com/news/home/20260824221319/en/)\n\nInvestor and Media Contact:\n\nNaresh Tanna\n\nChief Financial Officer\n\nnaresh.tanna@precisionbiosciences.com\n(mailto:naresh.tanna@precisionbiosciences.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7zbjrja","title":"Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study","author":"Business Wire","ticker":"DTIL","created":"2026-08-24T10:01:00.078Z","tickers":["DTIL"],"exchange":"NASDAQ","article_body":"Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study\n\n-First patient dosed with PBGENE-DMD, the first clinical gene-editing program\nfor DMD –\n\n-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified\nDuchenne Care Center and designated MDA Care Center–\n\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing\ncompany utilizing its novel proprietary ARCUS(®) platform to develop in vivo\ngene editing therapies for high unmet need diseases, today announced the\ndosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical\ntrial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy\n(DMD).\n\nPBGENE-DMD is Precision's wholly owned in vivo gene editing program designed\nto durably improve function. This novel approach, aiming to restore near\nfull-length dystrophin, is applicable for up to 60% of DMD patients with\nmutations in a key hot spot region. By employing two complementary ARCUS\nnucleases in a single AAV, PBGENE-DMD excises exons 45-55 of the dystrophin\ngene with the aim of restoring a near full-length functional dystrophin\nprotein that more closely resembles normal dystrophin than synthetic,\ntruncated microdystrophin approaches.\n\n“Dosing the first patient in the FUNCTION-DMD study earlier this month was a\nsignificant milestone for Precision BioSciences and for the Duchenne\ncommunity,” said Sam Collins, M.D., Senior Vice President, DMD Clinical\nDevelopment of Precision BioSciences. “PBGENE-DMD represents a paradigm\nshift from currently available approaches. Rather than delivering a highly\ntruncated form of synthetic dystrophin as many therapies in development do\ntoday, PBGENE-DMD is designed to permanently edit the patient’s own\ndystrophin gene to endogenously produce a near full-length, functional\ndystrophin protein. We are grateful to the patient, their family, and the\nclinical team for their commitment to advancing this important work, and we\nlook forward to reporting initial safety data by year-end 2026.”\n\n“A therapy designed to address the underlying genetic cause of Duchenne\nmuscular dystrophy represents a meaningful step forward for individuals and\nfamilies living with this condition,” said Aravindhan Veerapandiyan, M.D.,\nDirector of the Comprehensive Neuromuscular Program at Arkansas Children’s\nHospital. “We’re proud that our center was the first to dose a patient in\nthe FUNCTION-DMD study. PBGENE-DMD is designed to restore near full-length,\nfunctional dystrophin, and we look forward to evaluating its safety and\npotential to provide durable functional benefits. This innovation could open\nthe door to an entirely new approach for treating Duchenne.”\n\n“Seeing PBGENE-DMD move from research into the clinic turns the possibility\nof gene editing for Duchenne into reality — a novel approach that could\naddress some of the limitations of currently available therapies,” said Pat\nFurlong, President, Parent Project Muscular Dystrophy. “Families have been\nwaiting for options like this, and PPMD is encouraged to see this program\nadvance. We look forward to learning more as the study progresses and\ncontinuing collaboration on behalf of all our Duchenne families.”\n\nThe study is currently enrolling ambulatory DMD patients between the ages of 2\nand 7 with mutations between exons 45 and 55, representing up to 60% of boys\nliving with DMD, across multiple U.S. clinical trial sites. The study is\nactively recruiting patients at specialized Duchenne care centers with initial\nsafety data expected by year-end 2026.\n\nAbout the FUNCTION-DMD Trial\n\nThe Phase 1/2 FUNCTION-DMD study is enrolling ambulatory DMD patients between\nthe ages of 2 and 7 with mutations between exons 45 and 55 representing up to\n60% of boys with DMD. The objective of the FUNCTION-DMD study is to evaluate\nsafety, tolerability, and efficacy, including dystrophin protein expression\nand functional outcomes in patients living with DMD. For more information\nabout this clinical trial and contact information, please visit\nwww.clinicaltrials.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.clinicaltrials.gov&esheet=54593368&newsitemid=20260824221319&lan=en-US&anchor=www.clinicaltrials.gov&index=1&md5=746a66ffd606885e24566b2fb909b310)\nand search for NCT07429240.\n\nAbout PBGENE-DMD, A Muscle-Targeted Excision Program\n\nPBGENE-DMD is Precision’s development program for the treatment of DMD. DMD\nis a genetic disease caused by mutations in the dystrophin gene that prevent\nproduction of the dystrophin protein and affects approximately 15,000 patients\nin the U.S. alone. There are currently no approved therapies that can drive\ndurable and significant functional improvements over time. PBGENE-DMD is\ndesigned to improve function by employing two complementary ARCUS nucleases\ndelivered in a single AAV to excise exons 45-55 of the dystrophin gene. The\naim of this approach is to restore a near full-length functional dystrophin\nprotein within the body that more closely resembles normal dystrophin as\nopposed to synthetic, truncated microdystrophin approaches with potentially\nminimal functional benefit. The Phase 1/2 FUNCTION-DMD study is enrolling\nambulatory DMD patients with mutations between exons 45 and 55 impacting up to\n60% of boys with DMD. The clinical trial employs an appropriate immune\nmodulation regimen and safety monitoring program to treat ambulatory patients\nat world-class specialized DMD clinical sites.\n\nPBGENE-DMD was granted Orphan Drug Designation by the FDA in July 2025. The\nPBGENE-DMD program is eligible for a Priority Review Voucher (PRV) via the\nRare Pediatric Disease program, which was signed into law on February 3, 2026,\nas part of the Consolidated Appropriations Act of 2026. PBGENE-DMD received\nFast Track designation from the FDA in February 2026.\n\nAbout Precision BioSciences, Inc.\n\nPrecision BioSciences, Inc. is a clinical stage gene editing company dedicated\nto improving life (DTIL) with its novel and proprietary ARCUS(®) genome\nediting platform that differs from other technologies in the way it cuts, its\nsmaller size, and its simpler structure. These features are intended for ARCUS\nnucleases to drive more defined therapeutic outcomes. Using ARCUS, the\nCompany’s pipeline is comprised of clinical stage in vivo gene editing\ncandidates designed to deliver lasting cures for the broadest range of genetic\nand infectious diseases where no adequate treatments exist. For more\ninformation about Precision BioSciences, please visit\nwww.precisionbiosciences.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.precisionbiosciences.com&esheet=54593368&newsitemid=20260824221319&lan=en-US&anchor=www.precisionbiosciences.com&index=2&md5=1d97c988828ba62536563caed30f9532)\n.\n\nThe ARCUS(®) platform is being used to develop in vivo gene editing therapies\nfor sophisticated gene edits, including gene elimination (removing a genome\ne.g. viral DNA such as in the Company’s PBGENE-HBV program), excision\n(removing a large portion of a defective gene by delivering two ARCUS\nnucleases in a single AAV such as in the Company’s PBGENE-DMD program), and\ngene insertion (inserting DNA into gene to cause expression/add function).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements contained\nin this press release that do not relate to matters of historical fact should\nbe considered forward-looking statements, including, without limitation,\nexpectations around patient enrollment and data releases of PBGENE-DMD and the\nFUNCTION-DMD trial, including initial safety data expected by year-end 2026;\ntranslation of results in preclinical studies of PBGENE-DMD to clinical\nstudies in humans; expectations around PBGENE-DMD as a novel approach that\ncould address some of the limitations of currently available therapies; and\nthe expected use of an appropriate immune modulation regimen and safety\nmonitoring program to treat ambulatory patients at world-class specialized DMD\nclinical sites . In some cases, you can identify forward-looking statements by\nterms such as “aim,” “anticipate,” “approach,” “belief,”\n“believe,” “contemplate,” “could,” “design,” “designed,”\n“estimate,” “expect,” “goal,” “intend,” “look,” “may,”\n“mission,” “plan,” “possible,” “potential,” “predict,”\n“project,” “pursue,” “should,” “strive,” “suggest,”\n“target,” “will,” “would,” or the negative thereof and similar\nwords and expressions.\n\nForward-looking statements are based on management’s current expectations,\nbeliefs, and assumptions and on information currently available to us. These\nstatements are neither promises nor guarantees, and involve a number of known\nand unknown risks, uncertainties and assumptions, and actual results may\ndiffer materially from those expressed or implied in the forward-looking\nstatements due to various important factors, including, but not limited to,\nour ability to become profitable; our ability to procure sufficient funding to\nadvance our programs; risks associated with our capital requirements,\nanticipated cash runway, requirements under our current debt instruments and\neffects of restrictions thereunder, including our ability to raise additional\ncapital due to market conditions and/or our market capitalization; our\noperating expenses and our ability to predict what those expenses will be; our\nlimited operating history; the progression and success of our programs and\nproduct candidates in which we expend our resources; our limited ability or\ninability to assess the safety and efficacy of our product candidates; the\nrisk that other genome-editing technologies may provide significant advantages\nover our ARCUS technology; our dependence on our ARCUS technology; the\ninitiation, cost, timing, progress, achievement of milestones and results of\nresearch and development activities and preclinical and clinical studies,\nincluding clinical trial and investigational new drug applications; public\nperception about genome editing technology and its applications; competition\nin the genome editing, biopharmaceutical, and biotechnology fields; our or our\ncollaborators’ or other licensees’ ability to identify, develop and\ncommercialize product candidates; pending and potential product liability\nlawsuits and penalties against us or our collaborators or other licensees\nrelated to our technology and our product candidates; the U.S. and foreign\nregulatory landscape applicable to our and our collaborators’ or other\nlicensees’ development of product candidates; our or our collaborators’ or\nother licensees’ ability to advance product candidates into, and\nsuccessfully design, implement and complete, clinical trials; potential\nmanufacturing problems associated with the development or commercialization of\nany of our product candidates; delays or difficulties in our and our\ncollaborators’ and other licensees’ ability to enroll patients; changes in\ninterim “top-line” and initial data that we announce or publish; if our\nproduct candidates do not work as intended or cause undesirable side effects;\nrisks associated with applicable healthcare, data protection, privacy and\nsecurity regulations and our compliance therewith; our or our licensees’\nability to obtain orphan drug designation or fast track designation for our\nproduct candidates or to realize the expected benefits of these designations;\nour or our collaborators’ or other licensees’ ability to obtain and\nmaintain regulatory approval of our product candidates, and any related\nrestrictions, limitations and/or warnings in the label of an approved product\ncandidate; the rate and degree of market acceptance of any of our product\ncandidates; our ability to effectively manage the growth of our operations;\nour ability to attract, retain, and motivate executives and personnel; effects\nof system failures and security breaches; insurance expenses and exposure to\nuninsured liabilities; effects of tax rules; effects of any pandemic,\nepidemic, or outbreak of an infectious disease; the success of our existing\ncollaboration and other license agreements, and our ability to enter into new\ncollaboration arrangements; our current and future relationships with and\nreliance on third parties including suppliers and manufacturers; our ability\nto obtain and maintain intellectual property protection for our technology and\nany of our product candidates; potential litigation relating to infringement\nor misappropriation of intellectual property rights; effects of natural and\nmanmade disasters, public health emergencies and other natural catastrophic\nevents; effects of sustained inflation, supply chain disruptions and major\ncentral bank policy actions; market and economic conditions; risks related to\nownership of our common stock, including fluctuations in our stock price; our\nability to meet the requirements of and maintain listing of our common stock\non Nasdaq or other public stock exchanges; and other important factors\ndiscussed under the caption “Risk Factors” in our Annual Report on Form\n10-K for the annual period ended December 31, 2025 and Quarterly Report on\nForm 10-Q for the quarterly period ended June 30, 2026, as any such factors\nmay be updated from time to time in our other filings with the SEC, which are\naccessible on the SEC’s website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54593368&newsitemid=20260824221319&lan=en-US&anchor=www.sec.gov&index=3&md5=cb1f6bce7f2f2c46d90498a92f68128b)\nand the Investors page of our website under SEC Filings at\ninvestor.precisionbiosciences.com.\n\nAll forward-looking statements speak only as of the date of this press release\nand, except as required by applicable law, we have no obligation to update or\nrevise any forward-looking statements contained herein, whether as a result of\nany new information, future events, changed circumstances or otherwise.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260824221319/en/\n(https://www.businesswire.com/news/home/20260824221319/en/)\n\nInvestor and Media Contact:\n\nNaresh Tanna\n\nChief Financial Officer\n\nnaresh.tanna@precisionbiosciences.com\n(mailto:naresh.tanna@precisionbiosciences.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-24T10:01:00.147202821Z","server_sent_at_ms":1787565660147},"received_at":"2026-08-24T10:01:00.299Z","source_url":"https://www.businesswire.com/news/home/20260824221319/en/"},"analysis":{"id":"114600","press_release_id":"125654","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD study, marking the entry of its lead gene-editing candidate PBGENE-DMD into human trials.\n\nThe therapy targets Duchenne muscular dystrophy patients with mutations in exons 45-55, representing up to 60% of the DMD population, aiming to restore near full-length dystrophin.\n\nInitial safety data from the trial are expected by year-end 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"First-in-human dosing for PBGENE-DMD validates Precision's in vivo ARCUS platform and targets a large DMD subset."},"keyFigures":{"drugName":"PBGENE-DMD","phaseOfTrial":"Phase 1/2","customDimensions":{"data_readout":"year-end 2026","target_mutations":"exons 45-55","target_patient_percentage":"60%"}},"quotedText":"Dosing the first patient in the FUNCTION-DMD study earlier this month was a significant milestone for Precision BioSciences and for the Duchenne community","namedEntities":{"people":[{"name":"Sam Collins","role":"Senior Vice President, DMD Clinical Development"},{"name":"Aravindhan Veerapandiyan","role":"Director, Comprehensive Neuromuscular Program"},{"name":"Pat Furlong","role":"President"}],"products":["PBGENE-DMD","ARCUS"],"companies":[{"name":"Precision BioSciences, Inc.","ticker":"DTIL"},{"name":"Arkansas Children’s Hospital","relationship":"clinical trial site"},{"name":"Parent Project Muscular Dystrophy","relationship":"non-profit partner"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"First patient dosed in a Phase 1/2 study is a major de-risking event for a clinical-stage biotech, transitioning the lead asset PBGENE-DMD from preclinical to human testing."},"tickerRelevance":{"others":[],"primary":"DTIL"},"globalImportance":40,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"first-in-human-dosing","sectorWeight":"biotech"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD study, marking the entry of its lead gene-editing candidate PBGENE-DMD into human trials.\n\nThe therapy targets Duchenne muscular dystrophy patients with mutations in exons 45-55, representing up to 60% of the DMD population, aiming to restore near full-length dystrophin.\n\nInitial safety data from the trial are expected by year-end 2026.","key_figures":{"drugName":"PBGENE-DMD","phaseOfTrial":"Phase 1/2","customDimensions":{"data_readout":"year-end 2026","target_mutations":"exons 45-55","target_patient_percentage":"60%"}},"named_entities":{"people":[{"name":"Sam Collins","role":"Senior Vice President, DMD Clinical Development"},{"name":"Aravindhan Veerapandiyan","role":"Director, Comprehensive Neuromuscular Program"},{"name":"Pat Furlong","role":"President"}],"products":["PBGENE-DMD","ARCUS"],"companies":[{"name":"Precision BioSciences, Inc.","ticker":"DTIL"},{"name":"Arkansas Children’s Hospital","relationship":"clinical trial site"},{"name":"Parent Project Muscular Dystrophy","relationship":"non-profit partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-24T10:07:18.141Z","global_importance":40,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"first-in-human-dosing","sectorWeight":"biotech"}},"durationMs":113198,"modelName":"glm-4.7"}}